Research from Professor Anton Gartner’s group in the Centre for Gene Expression and Regulation has provided new information on the mechanics of cell division. Published today in Nature Communications, the work shows the role of a particular protein in this process that may have implications in understanding some types of breast and ovarian cancer.
Medical Research Council Protein Phosphorylation and Ubiquitylation Unit
Yumeng Mao is a Senior Scientist at AstraZeneca in Cambridge, UK who is interested in the development of small molecule drugs that potentiate anti-tumour immunity. Yumeng started his training in tumour immunology in 2009 with Dr. Karl-Erik Hellstrom at the University of Washington in Seattle, USA. Subsequently, he completed his doctoral and post-doctoral work at the Karolinska Institute in Stockholm, Sweden with Prof. Rolf Kiessling.
Grade 7 (starting points 29-31 only (£31,604–£33,518)
The family of deubiquitinating enzymes (DUBs) comprises more than 100 proteases that catalyze the removal of ubiquitin from substrate proteins, regulating the stability and/or activity of a large fraction of the proteome. DUBs perform key roles in virtually all physiological and pathophysiological processes.
The Medical Research Council’s Protein Phosphorylation and Ubiquitylation Unit (MRC PPU) is a world-leading research division, which is embedded within the School of Life Sciences at the University of Dundee. The major aim of the MRC PPU is to advance our understanding of the roles of protein phosphorylation and ubiquitylation in cell biology and human disease, in order to facilitate the development of new drugs to treat diseases caused by abnormalities in phosphorylation or ubiquitylation networks. We also aim to generate new reagents and improved technologies.
A sharing of current research with artists Charlie Murphy and Charles Robert Harrison and scientists Dr. Esther Sammler (MRC PPU and Ninewells Hospital) and Prof. Brian Day (UCL).
This event is programmed as part of the Trajectories exhibition at LifeSpace. Trajectories is a collaboration with the Created out of Mind research group based in The Hub at Wellcome Collection London, that aims to explore, challenge and shape perceptions and understandings of dementias through science and the creative arts.
Applications are invited for a postdoctoral position in the Ganley Lab to study the fundamentals of autophagy signalling. Recently we have uncovered multiple and unique pathways of in vivo mitophagy (autophagy of mitochondria – see (1,2)). However, we know very little about the signals that regulate these forms of mitophagy, which have been linked to diseases such as cancer and Parkinson’s.
The discovery that hyper-activating mutations in a protein kinase termed LRRK2 causes Parkinson’s, offers the prospect of elaborating new, potentially disease-modifying treatments in at least a subset of patients. Indeed, Phase I clinical trials with LRRK2 kinase inhibitors have commenced. Recent advances point towards LRRK2 regulating membrane trafficking events by phosphorylating a subgroup of Rab proteins and controlling their ability to bind cognate effector proteins.
Last week, at Review of the Year, Professor Julian Bow presented the annual School Prizes. The awards recognise excellence by members of the School in research and public engagement.